(MedPage Today) — Sulfonylureas were flagged for excess cardiovascular risk when used for additional glucose lowering in type 2 diabetes (T2D) in an observational comparative effectiveness study.
As second-line therapies atop metformin, individual…
Source link : https://www.medpagetoday.com/endocrinology/diabetes/116664
Author :
Publish date : 2025-07-24 21:19:00
Copyright for syndicated content belongs to the linked Source.
